1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sailong Pharmaceutical Group Co., Ltd.

Sailong Pharmaceutical Group Co., Ltd.

002898.SZ
Sailong Pharmaceutical Group Co., Ltd.CN flagShenzhen Stock Exchange
0.35
CNY
-0.01
- -
61.60MMarket Cap
Sailong Pharmaceutical Group Co., Ltd.
002898.SZ
(Shenzhen Stock Exchange)

Recent

price

0.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1.89
1.51
1.88
1.94
2.55
2.48
1.67
0.69
1.4
1.5
1.77
1.5
2.95
1.38
Revenue per Share
0.39
0.24
0.5
0.46
0.45
0.35
0.16
-0.38
-0.13
-0.21
0.05
-0.19
-0.69
-0.28
Basic EPS, GAAP
0.51
0.13
- -
0.21
-0.06
-0.75
-0.9
-0.36
0.02
-0.06
0.03
-0.42
-0.02
-0.17
Free Cash Flow per Basic Share
0.26
0.28
0.37
0.2
0.1
0.09
0.19
0.07
0.04
0.05
0.03
0.05
0.04
0.03
Dividend per Share
0.89
0.8
1.3
1.54
2.14
1.94
1.92
1.6
1.47
1.25
1.3
1.09
0.41
1.01
Book Value per Share
0.92
0.77
1.31
1.57
3.97
3.43
3.21
2.78
2.61
2.4
2.41
2.13
1.59
2.05
Tangible Book Value per Share
117
118
126
132
143
176
176
176
176
176
176
176
176
176
Basic Weighted Avg Shares
221
178
237
256
364
436
293
121
247
264
311
264
519
243
Sales/Revenue/Turnover
37.11
15.68
29.1
27.04
21.15
16.8
11.24
-60.95
-6.74
-9.9
3.75
-2.9
-3.95
-8.92
Operating Margin (%)
4
5
6
8
10
14
20
29
33
34
33
34
54
- -
Depreciation Expense
46
28
63
61
65
61
27
-67
-23
-37
10
-33
-121
-50
Net Income, GAAP
30.09
10.43
22.31
13.35
15.66
12.99
14.72
- -
- -
- -
57.36
- -
- -
- -
Effective Tax Rate (%)
20.73
15.83
26.66
23.94
17.71
13.96
9.37
-55.7
-9.45
-14.12
3.07
-12.58
-23.36
-20.45
Profit Margin (%)
59
54
87
84
364
278
148
51
23
-42
29
-5
-66
-32
Working Capital
- -
- -
- -
- -
- -
- -
- -
30
43
13
25
30
14
9
LT Debt
112
141
213
254
619
664
659
587
564
526
536
499
384
485
Total Equity
- -
16.01
27.16
23.88
14.31
9.76
4
- -
- -
- -
0.74
- -
- -
- -
Return on Invested Capital (%)
- -
24.95
47.31
32.61
24.75
18.41
7.57
- -
- -
- -
3.42
- -
- -
- -
Return on Capital (%)
- -
28.25
48.92
33.33
25.3
18.78
8.09
-21.72
-8.65
-15.58
4.24
-15.7
-91.69
-24.53
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
150
156
152
LT Borrowings
30
29
8
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
176
176
176
Market Capitalization
1,698
1,355
2,014

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
250
252
211
Cash, Cash Equivalents & STI
49
33
7
Accounts Receivable, Net
67
84
91
Inventories
94
89
88
Total Current Liabilities
255
258
243
Payables & Accruals
- -
- -
- -
ST Debt
150
156
152
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.94%
-7.74%
-23.06%
Free Cash Flow
1,248.36%
-446.52%
-94.16%
Net Income, GAAP
-71.61%
-62.62%
265.57%
Sales/Revenue/Turnover
18.92%
42.18%
96.82%
Total Cash Common Dividend
-6.91%
-6.35%
-25.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
87
63
45
264
2025
54
82
319
- -
519
2026
153
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
-0.19
2025
-0.01
- -
- -
- -
-0.69
2026
-0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.05
2025
0.01
- -
- -
- -
0.04
2026
- -
- -
- -
- -
- -
Similar Companies
MaaT Pharma S.A. (MAAT.PA)
Cutia Therapeutics (2487.HK)
Celyad Oncology S.A. (CYAD)
Kubota Pharmaceutical Holdings Co., Ltd. (4596.T)
Strategic Partners A/S (STRAP.CO)
Marinomed Biotech AG (MARI.VI)
Business
Sailong Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, and commercialization of pharmaceutical raw materials, intermediates, and prepared medicines across China. The company's diverse product portfolio features key offerings such as esomeprazole sodium, ornithine aspartate, argatroban, and milrinone, alongside a recently approved chest pain injection, injectable Nicorandil. Their therapeutic focus spans critical health areas including cardiovascular, cerebrovascular, nervous system, and digestive disorders, in addition to anti-infective, anti-bleeding, and analgesic applications. Founded in 2002, this high-tech enterprise centers its operations in Zhuhai, China, emphasizing technological innovation in its product development and nationwide sales network.